Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
In recent transactions, Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), a biopharmaceutical company with a market capitalization of $1.67 billion and impressive revenue growth of 56.6% in the last twelve months, sold a significant portion of the company’s Class A Ordinary Shares. According to the latest SEC filings, Ragosa executed sales of 20,343 shares on March 17 and March 19, 2025, at an average price of $23.10 per share, resulting in a total transaction value of approximately $469,923. According to InvestingPro analysis, the company maintains strong financial health with a "GREAT" overall score and robust liquidity, as evidenced by a current ratio of 3.3.
The transactions were part of a planned sale under a 10b5-1 trading plan, which Ragosa had set up in September 2024. These sales followed a series of option exercises, where Ragosa acquired shares at a price of $12.97 each, reflecting strategic financial planning on his part.
Following these transactions, Ragosa’s direct ownership stands at 23,382 shares. This activity is part of the ongoing management of equity holdings by company insiders, providing insights into their confidence and strategic decisions regarding the company’s stock. Investors often monitor such filings to gauge insider sentiment and potential future performance of the stock.
In other recent news, Kiniksa Pharmaceuticals announced plans to initiate a Phase 2/3 clinical trial for its heart drug KPL-387, targeting recurrent pericarditis, with the trial expected to start in mid-2025. This decision follows interactions with the U.S. Food and Drug Administration, with Phase 2 results anticipated in the latter half of 2026. Kiniksa aims to build on the success of its existing treatment, ARCALYST, which has generated over $800 million since its launch in 2021. The company has also decided to discontinue the development of abiprubart for Sjögren’s Disease. In financial developments, Goldman Sachs reiterated its Buy rating for Kiniksa, citing preliminary financial results for fiscal year 2024 that showed ARCALYST revenue surpassing expectations. Kiniksa reported a preliminary revenue of $416.4 million for FY24, marking a 79% increase compared to FY23. The company also provided guidance for ARCALYST revenue in FY25, projecting between $560 million and $580 million, exceeding Goldman Sachs’s forecast. The analyst from Goldman Sachs commended Kiniksa’s commercial execution with ARCALYST, considering it one of the more successful recent launches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.